These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27831505)

  • 1. Research needs in breast cancer.
    Cardoso F; Harbeck N; Barrios CH; Bergh J; Cortés J; El Saghir N; Francis PA; Hudis CA; Ohno S; Partridge AH; Sledge GW; Smith IE; Gelmon KA
    Ann Oncol; 2017 Feb; 28(2):208-217. PubMed ID: 27831505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned.
    Santa-Maria CA; Gradishar WJ
    JAMA Oncol; 2015 Jul; 1(4):528-34; quiz 549. PubMed ID: 26181262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment.
    Gu G; Dustin D; Fuqua SA
    Curr Opin Pharmacol; 2016 Dec; 31():97-103. PubMed ID: 27883943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
    de Melo Gagliato D; Jardim DL; Marchesi MS; Hortobagyi GN
    Oncotarget; 2016 Sep; 7(39):64431-64446. PubMed ID: 26824988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research priorities in prediction of response in early breast cancer.
    Carey LA
    Breast; 2019 Nov; 48 Suppl 1():S31-S33. PubMed ID: 31839156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New approaches for improving outcomes in breast cancer in Europe.
    Di Leo A; Curigliano G; Diéras V; Malorni L; Sotiriou C; Swanton C; Thompson A; Tutt A; Piccart M
    Breast; 2015 Aug; 24(4):321-30. PubMed ID: 25840656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Therapy for Premenopausal Women with HR
    Bardia A; Hurvitz S
    Clin Cancer Res; 2018 Nov; 24(21):5206-5218. PubMed ID: 29884743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.
    Austreid E; Lonning PE; Eikesdal HP
    Expert Opin Pharmacother; 2014 Apr; 15(5):681-700. PubMed ID: 24579888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Therapy for HER2-positive Breast Cancer.
    Wuerstlein R; Harbeck N
    Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.
    Brandão M; Pondé NF; Poggio F; Kotecki N; Salis M; Lambertini M; de Azambuja E
    Expert Rev Anticancer Ther; 2018 Jul; 18(7):629-649. PubMed ID: 29781317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?
    Toss A; Venturelli M; Peterle C; Piacentini F; Cascinu S; Cortesi L
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28054957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
    Shah AN; Cristofanilli M
    Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in chemical pharmacotherapy to manage advanced breast cancer.
    Gombos A; Awada A
    Expert Opin Pharmacother; 2017 Jan; 18(1):95-103. PubMed ID: 27927046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing Immunotherapy in Metastatic Breast Cancer.
    Mansour M; Teo ZL; Luen SJ; Loi S
    Curr Treat Options Oncol; 2017 Jun; 18(6):35. PubMed ID: 28534250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
    Conte P; Guarneri V; Bengala C
    Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Therapy in HER2-Positive Breast Cancer.
    Thill M; Kraft C; Friedrich M
    Oncol Res Treat; 2016; 39(5):295-302. PubMed ID: 27173915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies for ER+/HER2- metastatic breast cancer.
    Yamamoto-Ibusuki M; Arnedos M; André F
    BMC Med; 2015 Jun; 13():137. PubMed ID: 26059247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.